# Andrzej Kutner

Curriculum Vitae



#### Personal details

Current occupation: Department of Bioanalysis and Drug Analysis, Faculty of Pharmacy,

Medical University of Warsaw, 02-097 Warsaw, 1 Banacha Street,

Poland, https://wf.wum.edu.pl/en

e-mail address: <u>andrzej.kutner@wum.edu.pl</u>

Phone: +48 22 5720 726

Research identifier: ORCID:0000-0002-9518-4142

#### **Education**

1976 M.Sc. in chemistry, with distinction, Chemistry Department, University of Warsaw, "Synthesis and Baeyer-Villiger rearrangement of cholestanones", supervisor - Prof. Władysław J. Rodewald

1982 Ph.D. in chemical sciences, with distinction, Chemistry Department, University of Warsaw, thesis: "Studies on natural cholanoic acids of therapeutic potential", supervisor – Dr. Romana Jaworska

1994 D.Sc. (habilitation), Pharmacy Department, Medical Academy of Warsaw (currently: Medical University of Warsaw), "Studies on active analogs of vitamins D"

2011 professor in pharmaceutical sciences, Pharmacy Department, Medical Academy of Warsaw (currently: Medical University of Warsaw)

# Research positions and honours

1976 – 2018 Pharmaceutical Research Institute (PRI), Warsaw, PL, from research assistant to professor
1984 - 1986 and 1987 University of Wisconsin-Madison, Department of Biochemistry, USA, research associate with Prof. Hector F. DeLuca
1990 - 1997 Head, Contract research and manufacturing with a pharmaceutical company Solvay B.V., The Netherlands, "Design, synthesis and manufacturing of vitamin D compounds"
1993 New York University, Department of Chemistry, USA, visiting scientist with Prof. Stephen R. Wilson

Visiting Professor, short visits and lectures in USA at: University of Minnesota,
Duluth, Chemistry Dept., with Prof. Ronald Caple; University of California,
Riverside, Chemistry Dept., with Prof. William H. Okamura; University of
Wisconsin-Madison, Biochemistry Dept, with Prof. H.F. DeLuca
Guest Editor, Current Pharmaceutical Design, Special Issue "Vitamin D
Inhibitors of Cancer Growth"
Research Director of PRI, three consecutive terms
"Strategies of Pharmaceutical syntheses", monographic course of lectures for
M.Sc's students at the Chemistry Department, University of Warsaw
Chair, Scientific Board, PRI
External Expert to National Science Center, Cracow, PL
Member, National Committee for evaluation of grant proposals, National Center
for Research and Development, Operational Program of Innovative
Economy PO IG 2007-2012, Action 1.3.2., patent protection of R&D,
representative of scientific community, Warsaw, PL
External Expert, National Center for Research and Development, Warsaw, PL
Member of the Panel of Chemical and Pharmaceutical Sciences, World
Undergraduate Award, Ireland
External Expert of the Ministry of Development, Warsaw, PL
Official representative of the National Center of Research and Development to
the Bridge Alfa Program, Life Sciences and RSD Funds and reviewer of
multiple R+D Projects, Warsaw, PL
Medical University of Warsaw, Faculty of Pharmacy, Department of
Bioanalysis and Drug Analysis, professor
Austrian Science Fund (FWF), independent reviewer

#### EU funded grants

- 2005-2008 FP6-LSH-2004-1.2.1-5 IFESCIHEALTH, Project acronym: EUMAPP, European Union Microdose AMS Partnership Programme, "Microdosing studies to gain enhanced absorption, distribution, metabolism, excretion (ADME) parameters for biopharmaceuticals", Project lead at PRI, grant ID:18672, <a href="https://cordis.europa.eu/project/rcn/78419/factsheet/en">https://cordis.europa.eu/project/rcn/78419/factsheet/en</a>
- 2013-2016 FP7-PEOPLE-2012-ITN, Project acronym: DECIDE, "Decision-making within cells and differentiation entity therapies", Co-chair and WP2 Lead, grant ID: 315902, https://www.birmingham.ac.uk/generic/decide/partners/index.aspx
- 2018-2022 Horizon 2020, MSCA, RISE, Project acronym: ORBIS, "Open Research Biopharmaceutical Internship Support", Co-chair and WP1 Co-Lead, 2018, grant ID: 778051, <a href="http://www.orbisproject.eu">http://www.orbisproject.eu</a>

### National grants

National Centre for Research and Development (NCRD, Warsaw, PL), Project WND-POIG.01.03.01-14-062/09 "Innovative technologies of *cardiovascular* drugs of a special therapeutic and social importance", Operational Program of Innovative Economy (OPIE 2007-

2013 (extended for 2014), Priority 1, Activity 1.3, Support for R&D Projects for entrepreneurs completed by research entities, Sub-activity 1.3.1, set of five projects, lead.

NCRD Project UDA-POIG.01.03.01-14-069/08-00 "Development of innovative technologies of *oncologic* drugs of a special therapeutic and social significance" OPIE, 2007-2013, Priority 1, Activity 1.3, Support for R&D Projects for entrepreneurs completed by research entities, Sub-activity 1.3.1, set of five projects, lead.

NCRD Project UDA-POIG.01.03.01-14-068/08-00 "Development of innovative technologies of *ophthalmic* drugs of a special therapeutic and social significance" OPIE 2007-2013, Priority 1, Activity 1.3, Support for R&D Projects for entrepreneurs made by research entities, Sub-activity 1.3.1, set of five projects, lead.

Project KB/150/12.852/IT1-B/U/08, Technological Initiative of the Ministry of Science and Higher Education, 2009-2013, "Development of a synthetic technology of the pharmaceutical substance *paricalcitol* and its dosage form used in chronic renal failure of dialyzed patients", scientific consultant.

Project KB/151/13364/IT1-B/U/08, Technological Initiative of the Ministry of Science and Higher Education, 2008-2012 (extended, 2014), "Development of a synthetic technology of the pharmaceutical substance *capecitabine* and its dosage form used as an anticancer drug", lead.

#### Awards

- 2009 Award of the Institute of Physical Chemistry of the Polish Academy of Sciences for the best paper of 2008, S.L. Randzio, A. Kutner, Metastability and instability of organic crystalline substances, *J. Phys. Chem.* B, **112**, 1435-1444 (2008)
- 2011 Team award, Gold Medal, "Innovative manufacturing process of tacalcitol an active substance of an antipsoriatic drug", 60<sup>th</sup> Brussels INNOVA, Belgium
- 2012 Team award, Bronze Medal, International Warsaw Invention Show IWIS 2012 "A novel convergent synthesis of antiglaucoma  $PGF_{2\alpha}$  analogue travoprost"
- 2016 Team award, Gold Medal, International Warsaw Invention Show IWIS 2016 "Prasugrel – innovative technology of a drug product".
- 2018 Team award, ERiNET Innovatoren Preis 2018, International Trade Fair Ideas Inventions New Products, IENA'2018, Nurnberg, Germany, "Molecularly imprinted polymers employing carbazole and tiophene monomers and their application as recognition layers in chemosensors of aripiprazole and human chorionic gonadotropin"

## Recent publications

Nachliely M, Trachtenberg A, Khalfin B, Nalbandyan K, Cohen-Lahav M, Yasuda K, Sakaki T, **Kutner A**, Danilenko M. Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells *in vitro* and inhibit leukemia progression in xenograft mouse model. *J. Steroid Biochem. Mol. Biol.*, 2019, 189, 8-16, <u>doi:10.1016/j.jsbmb.2018.11.017</u>, IF 4.561.

Kotlarz A, Przybyszewska M, Swoboda P, Neska J, Miłoszewska J, **Kutner A**, Markowicz S. Imatinib inhibits the regrowth of human colon cancer cells after treatment with 5-FU and cooperates with vitamin D analogue PRI-2191 in downregulation of expression of stemness-related genes in 5-FU refractory cells. *J. Steroid Biochem. Mol. Biol.*, 2019, 189, 48-62, <u>doi:10.1016/j.jsbmb.2019.02.003</u>, IF 4.561.

Milczarek M, Rossowska J, Wietrzyk J, Stachowicz M, **Kutner A**, Kłopotowska D. Tacalcitol increases the sensitivity of colorectal cancer cells to 5-fluorouracil by downregulating the thymidylate synthase. *J Steroid Biochem. Mol. Biol.*, 2019, 190, 139-151, *doi:10.1016/j.jsbmb.2019.03.017*, IF 4.561.

Anisiewicz A, Filip-Psurska B, Pawlik A, Nasulewicz-Goldeman A, Piasecki T, Kowalski K, Maciejewska M, Jarosz J, Banach J, Papiernik D, Mazur A, **Kutner A**, Maier JA, Wietrzyk J. Calcitriol analogues decrease lung metastasis but impair bone metabolism in aged ovariectomized mice bearing 4T1 mammary gland tumors. *Aging Dis.*, 2019, 10, 977-991, *doi: 10.14336/AD.2018.0921*, IF 5.058.

Maj E, Trynda J, Maj B, Gębura K, Bogunia-Kubik K, Chodyński M, **Kutner A**, Wietrzyk J. Differential response of lung cancer cell lines to vitamin D derivatives depending on EGFR, KRAS, p53 mutation status and *VDR* polymorphism. *J. Steroid Biochem. Mol. Biol.*, 2019, 193, 105431, *doi: 10.1016/j.jsbmb.2019.105431*, IF 4.561.

Berkowska K, Corcoran A, Grudzień M, Chodyński M, **Kutner A**, Marcinkowska E. Investigating the role of megalin in semi-selectivity of side-chain modified 19-*nor* analogs of vitamin D. *Int. J. Mol. Sci.* 2019, 20, 4183, <u>doi:10.3390/ijms20174183</u>, IF 3.257.

**Kutner A**, Brown G. Vitamins D: Relationship between Structure and Biological Activity, *Int. J. Mol. Sci.*, 2018, 19, 2119, <u>doi:10.3390/ijms19072119</u>, IF 3.257.

Brown G, **Kutner A**, Marcinkowska E (2018) Vitamin D and leukaemia. In *Extraskeletal Effects of Vitamin D*. Liao, E.P., Ed.; Springer: New York, USA,; pp. 115–134.

Wanat M, Malińska M, **Kutner A**, Wozniak K. Effect of vitamin D conformation on interactions and packing in the crystal lattice, *Cryst. Growth Des.* 2018, 18, 3385-3396, *doi: 10.1021/acs.cgd.8b00091*, IF 3.972.

Maj E, Filip-Psurska B, Milczarek M, Psurski M, **Kutner A**, Wietrzyk J. Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model. *Int. J. Oncol.* 2018, 52, 337-366, doi:10.3892/ijo.2017.4228, IF 3.018.

Alluther